GLP-1 Anti-Obesity Drugs Boost Testosterone and Enhance Health Outcomes
Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone levels in men with obesity or type 2 diabetes. Challenges in accessing these medications due to supply shortages are noted, but significant health benefits remain achievable with lifestyle interventions.
At the Endocrine Society's annual meeting in San Francisco, researchers highlighted positive effects of GLP-1 anti-obesity medications on testosterone levels and health outcomes for men with obesity or diabetes. This insight was presented by Dr. Shellsea Portillo Canales from SSM Health St. Louis University Hospital.
In the study, 110 men received treatments with semaglutide, dulaglutide, or tirzepatide, showing significant testosterone improvements over 18 months. While causation wasn't definitively proven, researchers observed an association between weight loss and enhanced testosterone figures.
Despite access obstacles to these medications, a parallel study from Calibrate's Kaelen Medeiros revealed that even intermittent treatment paired with lifestyle changes leads to commendable weight loss. Meanwhile, researchers emphasize the potential of osteoporosis drugs in reducing elderly patients' fracture-related health risks.
(With inputs from agencies.)
ALSO READ
Health Rounds: 3D printed insulin-producing cells show promise for type 1 diabetes in lab tests
Lifestyle Changes Triumph Over Drugs in Diabetes Prevention
Bret Michaels shares he may "have to rearrange" tour schedule after diabetes scare
Wockhardt Shifts Focus from US Generics to Innovation in Antibiotics and Diabetes
Sugar.fit Revolutionizes Diabetes Care with Research at American Diabetes Association
Google News